← Back to all signals
RESEARCH PAPER ANALYSIS

ML-Based Multidomain Speech Biomarkers for Multiclass Parkinson's Severity: An Indian Corpus and Clinically Calibrated Labels.

The authors collected a Malayalam speech corpus and used multidomain acoustic features with mRMR and grouped permutation importance to train 12 classifiers, achieving very high subject-dependent accuracy (~0.96) and moderate subject-independent generalization (accuracy up to ~0.75, macro-F1…

PMID41986191
JournalJournal of voice : official journal of the Voice Foundation
Publication Date2026-04-14
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

The authors collected a Malayalam speech corpus and used multidomain acoustic features with mRMR and grouped permutation importance to train 12 classifiers, achieving very high subject-dependent accuracy (~0.96) and moderate subject-independent generalization (accuracy up to ~0.75, macro-F1…

WHY IT MATTERS

Research significance

Offers a language-specific, speaker-robust speech biomarker and feature-selection pipeline useful for remote staging and monitoring in PD clinical assessments and trials, but it provides little mechanistic or therapeutic discovery insight.

ABSTRACT

Source abstract

OBJECTIVE: Speech provides a lightweight window into articulatory and phonatory impairment in Parkinson's Disease (PD), yet clinically reliable severity staging has to extend across speakers. This study develops a PD severity classification framework which compares Subject Dependent (SD) and subject-independent (SI) settings on clinically calibrated labels such as mild, severe, and Healthy Controls, using a newly collected Indian conversational linguistic phrase in Malayalam language. METHODS: The key acoustic features were extracted, and include prosodic, phonatory, perturbation, noise, and spectral-cepstral descriptors. The feature selection approach on SD is minimum redundancy maximum relevance (mRMR) and for SI, both mRMR and grouped permutation importance (GPI) applied separately with grouped inner cross validation for leakage-safe feature selection. Further evaluation carried out using trained and tuned 12 classical classifiers-K-Nearest Neighbors (KNN), Support Vector Machine-Radial Basis Function kernel (SVM-RBF), logistic regression (LR), Ridge, GaussianNB, quadratic discriminant analysis (QDA), Extra Tree, Random Forest, Gradient Boosting, AdaBoost, SVM-Linear, and Multi-Layer Perceptron (MLP). RESULTS: In SD evaluation, the scores were inflated in model SVM-RBF as Acc 0.961, micro-AUC ≈ 0.999 using mRMR approach. Under SI (unseen speakers) evaluation, GPI's top-20 features generated the best result from the SVM-Linear classifier with Acc 0.736 (macro-F1 as 0.682, micro-AUC 0.891), and the classifier LR produced the best accuracy of 0.747 (macro-F1 0.732, micro-AUC 0.883). In comparison to mRMR, GPI matched the macro-F1 in SI evaluation but improved accuracy/AUC (Area Under the Curve) on nonlinear models. CONCLUSION: This study shows the potential of the multidomain acoustic features that effectively classify the PD severity on speech task in both SD and SI settings. While SD evaluation achieved higher accuracy (∼0.961), the SI setup reflects the real-world generalization and showed strong performance with macro-F1 ranges from 0.55 to 0.73, accuracy up to ∼0.747. These results show relative performance to prior works and highlight the need for speaker-robust modeling, balanced tasks, and multimodal integration to bridge the SD-SI performance gap.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic